logo

IDYA

IDEAYA Biosciences·NASDAQ
--
--(--)
--
--(--)
2.07 / 10
Underperform

Corporate fundamentals are rated weak (2.1/10). Key concerns include subpar net profit and revenue metrics relative to market value, while cash and inventory management show some strength. Overall, the balance sheet and profitability remain areas of vulnerability.

Fundamental(2.07)SentimentTechnical

Analysis Checks(5/10)

Revenue-MV
Value-0.35
Score1/3
Weight13.24%
1M Return5.20%
Inventory turnover ratio
Value47.85
Score3/3
Weight11.63%
1M Return5.26%
Gross profit margin (%)
Value100.00
Score1/3
Weight-1.02%
1M Return-0.54%
Profit-MV
Value0.46
Score2/3
Weight19.82%
1M Return7.79%
PB-ROE
Value0.96
Score0/3
Weight9.05%
1M Return3.56%
Current assets turnover ratio
Value0.28
Score2/3
Weight2.32%
1M Return1.15%
Fixed assets turnover ratio
Value24.25
Score3/3
Weight1.69%
1M Return0.86%
Asset-MV
Value-0.50
Score1/3
Weight24.02%
1M Return8.74%
Cash-MV
Value0.74
Score2/3
Weight19.84%
1M Return7.73%
Net profit / Total profit (%)
Value100.00
Score0/3
Weight-0.59%
1M Return-0.30%
Is IDYA undervalued or overvalued?
  • IDYA scores 2.07/10 on fundamentals and holds a Premium valuation at present. Backed by its -2.83% ROE, -74.82% net margin, -8.50 P/E ratio, 2.58 P/B ratio, and 18.88% earnings growth, these metrics solidify its Underperform investment rating.